|
| Press Releases |
|
 |
|
| Friday, May 7, 2021 |
|
|
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications |
| Eisai Co., Ltd.and Merck & Co., Inc., Kenilworth, N.J., U.S.A. today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for applications seeking two new approvals for the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. more info >> |
|
| Wednesday, April 28, 2021 |
|
|
RESONA and Eisai Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia in Saitama Prefecture, Japan |
| Saitama Resona Bank, Limited, a corporation of the Resona Group, and Eisai Co., Ltd. announced today that both parties have entered into a business alliance agreement for building an ecosystem. more info >> |
|
| Friday, April 23, 2021 |
|
|
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan |
| Eisai Co., Ltd. and MSD K.K. announced today an application submission in Japan for the additional indication of Eisai's in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA. more info >> |
|
|
Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies |
| Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Gilead submitted an application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for approval of filgotinib for an additional indication to treat patients with moderately to severely active ulcerative colitis. more info >> |
|
|
Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer's Disease |
| Eisai Co., Ltd. announced today that Biogen has disclosed, in its Q1 2021 Earnings Press Release issued on April 22, its current submission status of the Marketing Authorization Applications (MAA) for aducanumab. more info >> |
|
| Tuesday, April 20, 2021 |
|
|
Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer's Disease with Lecanemab, an Anti-Abeta Protofibril Antibody, in the peer-reviewed journal Alzheimer's Research and Therapy. more info >> |
|
| Wednesday, April 14, 2021 |
|
|
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting |
| Eisai Co., Ltd. announced today that the company will conduct presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401). more info >> |
|
| Monday, April 12, 2021 |
|
|
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021 |
| Eisai Co., Ltd. announced that its animation "Leave No One Behind-Disease of Neglected People" which features activities for the elimination of lymphatic filariasis (LF) has received the Animation Award at the International Society for Neglected Tropical Diseases (ISNTD) Festival 2021. more info >> |
|
| Wednesday, March 31, 2021 |
|
|
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries |
| KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four ASEAN (Association of Southeast Asian Nations) member states; Thailand, the Philippines, Malaysia and Brunei. more info >> |
|
|
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan |
| Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., (known as MSD outside the United States and Canada) announced today that Eisai has submitted an application in Japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
TruMerit Launches Global Credential for First-Level, General Nurses
Aug 6, 2025 09:00 HKT/SGT
|
|
|
NEFECON(R) Receives NMPA Approval for Production Expansion in China,as Everest Medicines Accelerates Accessibility and Capacity Efforts
Aug 5, 2025 23:22 HKT/SGT
|
|
|
Robot Boom in HK: Shoucheng Holdings at the Forefront
Aug 5, 2025 23:18 HKT/SGT
|
|
|
MHI Selected to Enter Next Stage Procurement Process for Australia's New General-Purpose Frigates
Aug 5, 2025 22:02 JST
|
|
|
Traveler Care Launches Global Medical Dispatch Platform to Help Travel Insurance Companies Cut ER Claims by 80%
Aug 4, 2025 21:00 HKT/SGT
|
|
|
Atlas Lithium's Neves Project Completes Definitive Feasibility Study Estimating 145% IRR and 11-Month Payback
Aug 4, 2025 20:39 HKT/SGT
|
|
|
12 New Companies Join Toyota Woven City as Inventors
Aug 4, 2025 21:09 JST
|
|
|
Honda HRC Wins 46th Suzuka 8 Hours Endurance Road Race
Aug 4, 2025 20:43 JST
|
|
|
'Waste-to-Value, Industry Upgrade, and GBA Co-Creation' Technology Forum Brings Together Top Experts, Driving Green Industry Advancement Through Frontier Technologies 
Aug 4, 2025 11:19 HKT/SGT
|
|
|
MUFG Bank and Fujitsu collaborate on preventive health ecosystem to address societal challenges
Aug 4, 2025 11:00 JST
|
|
|
Michael Owen Becomes the New Face of GK8: Fastest Growing iGaming Brand
Aug 3, 2025 13:00 HKT/SGT
|
|
|
Risetcar's driverless taxis are performing well in the US, with Jakarta operations set to launch soon
Aug 2, 2025 21:30 HKT/SGT
|
|
|
Kuvi.ai Launches Private Beta of Agentic Finance OS with Seed Round Led by Moon Pursuit Capital
Aug 2, 2025 11:30 HKT/SGT
|
|
|
Rust Mobile Revealed With Official Trailer, First Hands-on Demo Set for Gamescom 2025
Aug 2, 2025 00:30 HKT/SGT
|
|
|
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies
Aug 2, 2025 00:02 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
